Flagship reveals new agreements under Pfizer link-up

Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer.

These agreements are the most recent collaborations under Flagship’s strategic partnership with Pfizer (NYSE: PFE) that was announced in July 2023, and will use the US pharma giant’s expertise in early discovery and development for new targeted therapies.

Ampersand claims that its platform enables a new way of programming medicines that work precisely where needed in the body and nowhere else, while Montai is using AI to decode untapped diverse chemistry to develop breakthrough oral medicines to address unmet patient needs across chronic disease.